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Abstract
Antiestrogen resistance is a major clinical problem in the treatment of breast cancer. Altered 
growth factor signaling with estrogen receptor (ER) α has been shown to be associated with the 
development of resistance. Gene expression profiling was utilized to identify MAPK phosphatase 
3 (MKP3) whose expression was correlated with response to the antiestrogen tamoxifen in both 
patients and in vitro derived cell line models. Overexpression of MKP3 rendered ERα-positive 
breast cancer cells resistant to the growth inhibitory effects of tamoxifen, and enhanced tamoxifen 
agonist activity in endometrial cells. MKP3 overexpression was associated with lower levels of 
activated ERK1,2 phosphorylation in the presence of estrogen, but that estrogen deprivation and 
tamoxifen treatment decreased MKP3 phosphatase activity, leading to an up-regulation of 
pERK1,2 MAPK, phosphoserine 118 of ERα, and cyclin D1. The MEK inhibitor PD98059 
blocked tamoxifen-resistant growth. Accumulation of reactive oxygen species was observed with 
tamoxifen treatment of MKP3 overexpressing cells, and antioxidant treatment increased MKP3 
phosphatase activity, thereby blocking resistance. Furthermore, PD98059 increased the levels of 
phospho-JNK in tamoxifen-treated MKP3 overexpressing cells, suggesting an interaction between 
MKP3 levels, activation of ERK1,2 MAPK, and JNK signaling in human breast cancer cells. 
MKP3 represents a novel mechanism of resistance which may be a potential biomarker for the use 
of ERK1,2 and/or JNK inhibitors in combination with tamoxifen treatment.
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Introduction
The steroid hormone estrogen can stimulate breast tumor growth, and agents that inhibit 
estrogen synthesis, or antiestrogens like tamoxifen (Tam) which block its receptor, are the 
standard therapies offered to women with estrogen receptor (ER)α-positive cancer. In many 
cases, however, these therapies eventually fail. One current hypothesis is that ERα remains 
essential to the problem of resistance, due to its molecular crosstalk with growth factors, 
and/or downstream intracellular signaling molecules. There is also a growing body of 
evidence implicating the mitogen-activated protein kinase extracellular signal-regulated 
kinases ERK 1,2 MAPKs in the growth factor phosphorylation cascade, and its interaction 
with ERα signaling in TR (1). Indeed, phosphorylation of ERK 1,2 MAPK has been 
associated with a poorer quality of response to Tam in breast cancer patients (2).
We know that ERα can be phosphorylated by activated MAPK, resulting in ligand-
independent transcriptional activity (3). An emerging area of research in MAPK signaling is 
the role of specific protein phosphatases in the control of MAPK activation, and their role in 
specific biological responses. MAPK phosphatase 3 (MKP3, also called dual specificity 
phosphastase 6 [DUSP6] and Pyst1) is a member of a phosphatase family that inactivates 
MAPK function [reviewed in (4)]. MKP3 is in a regulatory feedback loop with ERK 1,2 
MAPK (5, 6). How MKP3 impacts on ERα and MAPK function in breast cancer cells, and 
how a resultant feedback loop impacts on the generation of TR is the subject of the present 
study.
Materials and Methods
Reagents, Hormones, and Antibodies
17β-Estradiol (E2) and 4-hydroxy-tamoxifen (4-OH-Tam) were from Sigma (St. Louis, 
MO). ICI 182,780 was obtained from Astrazeneca (Macclesfield, UK). The MEK1,2 
inhibitor PD98059 and GSH were from Calbiochem (La Jolla, CA). 2′,7′-
dichlorodihydrofluorescein diacetate (H2DCF-DA) was obtained from Molecular Probes 
( Eugene, Oregon). p-nitrophenyl phosphate (pNPP) and pNPP assay buffer were obtained 
from Upstate Biotechnology (Charlottesville, VA).
Construction of siRNA Plasmids
The MKP3 siRNA oligonucleotides containing the sequence 
GCTCAATCTGTCGATGAAC, corresponding to the MKP3 coding region from #1283 to 
1301, the MKP1 siRNA oligonucleotides containing the sequence 
GGAGGATACGAAGCGTTTT, corresponding to the MKP1 coding region from #615 to 
623, or GCATCATCTCTCCCAACTT, corresponding to the MKP1 coding region from 
#1126 to 1144 were inserted into RNAi-Ready pSiren-Retro-Q vector (Clontech, Pal Alton, 
CA). The control RNAi oligonucleotide was purchased from Clontech.
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Tumor Specimens and Expression Microarray Analysis
A cohort of frozen breast tumor specimens from nine patients who received adjuvant Tam 
was selected from the tumor bank of The Breast Center, Baylor College of Medicine, for use 
in the RNA analyses. This study was approved by the Baylor College of Medicine 
Institutional Review Board in accordance with federal human research study guidelines. 
Within this cohort, metastatic tumors from five patients who developed their recurrent lesion 
within 1-11 months while undergoing Tam treatment (Tam-resistant), and four primary 
tumors that were collected at the time of initial diagnosis from patients who remained 
disease-free for 93-123 months with a median follow-up of 106 months (Tam-sensitive) 
were included.
Total cellular RNA was extracted from 100 mg of pulverized tumor powder using Trizol 
reagent (InVitrogen) followed by Qiagen RNeasy column purification (Qiagen, Valencia, 
CA). cRNA was hybridized onto Affymetrix HGU95A GeneChips using recommended 
procedures for hybridization, washing, and staining with streptavidin–phycoerythirin. The 
GeneChips were scanned, and feature quantitation was performed using MAS5.0 
(Affymetrix). Data were normalized using the invariant set method, and modeled to estimate 
expression using the Perfect-match only model-based expression index as implemented in 
dChip (7); class comparisons were performed using BRB Array Tools developed by Drs. 
Richard Simon and Amy Peng (http://linus.nci.nih.gov/BRB-ArrayTools.html), and t-tests 
were performed with randomized variance modeling (8).
qRT-PCR
Real-time quantitative RT-PCR (qRT-PCR) was performed utilizing the 7700 Sequence 
Detector (Applied Biosystems, Foster City, CA) Specific quantitative assays for MKP3 were 
developed using Primer Express software version 1.0 for mMcintosh (Applied Biosystems) 
following the recommended guidelines based on sequences from Genbank. Primer 
sequences for human MKP3 were: forward primer, GTGGCACCGACACAGTG, reverse 
primer, CCCGTATTCTCGTTCCAG, human MKP3 RNA probe sequence, 
TCTACGACGAGAGCAGCAGCG, assay length, 65 nt; Primer sequences for human 18S 
rRNA were: forward primer, CGGCTTAATTTGACTCAACAC, reverse primer, 
ATCAATCTGTCAATCCTGTCC, human 18S rRNA probe sequence, 
AAACCTCACCCGGCCCG, assay length, 68 nt. Synthetic DNA oligos used as standards 
(sDNA) encompassed the entire 5′ – 3′ amplicon for the assay (Biosource, Camarillo, CA). 
Final normalized data are presented as the ratio of MKP3 to 18S RNA.
Cells and Stable Transfection
The paired TR breast cancer cell lines, MCF-7/WT/ and MCF-7/TR or T47D/WT and 
T47D/TR have been previously described (9). Ishikawa endometrial cancer cells were 
kindly provided by Dr. Carolyn Smith. MCF-7 cells were originally obtained from Dr. 
Benita Katzenellebogen, but have been maintained in our laboratory for over 15 years (10). 
These MCF-7 cells were maintained in Minimal Essential Medium (MEM, InVitrogen) 
supplemented with 5% fetal bovine serum (Summit Biotechnology, Fort Collins, CO), 200 
U/ml penicillin, and 200 μg/ml streptomycin. Cells were incubated at 37 °C in 5% CO2. To 
generate MCF-7 and Ishikawa cells stably overexpressing MKP3, pcDNA3-MKP3-V5 (11) 
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or empty vector (pcDNA3-His-V5, InVitrogen), were transfected as described (10), and 
positive clones were identified using immunoblot analysis with an anti-V5 antibody (1:5000 
dilution). Ishikwa cells was transfected with pcDNA3-MKP3-V5, empty vector (pcDNA3-
His-V5, InVitrogen), MKP3 siRNA vector, MKP1 siRNA vectors, or siRNA control vectors 
and transfectants were selected with either 800μg/ul G418, or 1μg/ul puromycin.
Cell Extracts and Immunoblots
Cells were starved in phenol red–free (PRF), serum-free MEM (Specialty Media, 
Phillipsburg, NJ) for 48 hours, and were then treated for 2 hours with vehicle (ethanol), 
estrogen (100 nM), or 4-hydroxytamoxifen (Tam) (100 nM). Equal amount of cell extracts 
were resolved under denaturing conditions by electrophoresis in 8-10% polyacrylamide gels 
containing sodium dodecyl sulfate (SDS-PAGE), and transferred to nitrocellulose 
membranes by electroblotting (Schleicher & Schuell, Keene, NH). After blocking of the 
transferred nitrocellulose membrane, they were incubated with primary antibodies either for 
1 hour at room temperature (anti-ERα, 1:100 dilution; anti-AIB1, 1:100 dilution; anti-
ERK2, 1:500 dilution; anti-Cyclin D1, 1:500 dilution; anti-PR, C-19, 1:200 dilution; anti-
p190, 1:1000 dilution; anti-V5, 1:5000 dilution; anti-MKP-1, 1:200 dilution), or overnight at 
4°C (anti- phospho MAPK, phospho-JNK, phospho-p38, phospho-Ser118-ERα, MAPK 
p42/44, JNK, and p38 were used at 1:1000 dilution), and then incubated with secondary 
antibodies for 1 hour at room temperature and developed with Enhanced 
Chemiluminescence Reagents (Amersham Pharmacia Biotech, Piscataway, NJ).
ROS Measurements
MKP3 overexpressing MCF-7 cells were treated with vehicle control, estradiol, or Tam for 2 
hours as described before, then the cells were trypsinized, washed two times with 
prewarmed (37°C) PBS, and then resuspended into prewarmed PBS supplemented with 
either DMSO or 5 μM of a fluurogenic probe for ROS—2′,7′-dichlorodihydrofluorescein 
diacetate (H2DCF-DA) (Molecular Probes) at 300,000 cells/ml, and incubated at 37°C for 
another 2 hours. Fluorescence (excitation wavelength: 480 nm, emission wavelength: 530 
nm) was measured using a fluorometer in a 96 well plate (300 μl/well) and normalized by 
subtracting fluorescence of DMSO incubated samples. The experiment was performed in 
triplicate.
Immunoprecipitation and Phosphatase Assays
MKP3-overexpressing and control transfected MCF-7 cells were treated as described above 
with ethanol, E2, or Tam, with or without GSH, and lysed in buffer containing 20 mM Tris-
HCl (pH 7.0), 150 mM NaCl, 1% Triton X-100, 0.25 M sucrose, 1 mM EDTA, 1 mM EGTA, 
0.1% β-mercaptoethanol, 1 mM PMSF, and 1 μg/ml leupeptin . A phosphatase reaction was 
performed as described {Kim, 2003 #2664and the nonenzymatic hydrolysis of the substrate 
was corrected by measuring the control vector transfected immunoprecipitates. The amount 
of product p-nitrophenol was determined from the absorbance at 405 nm. The phosphatase 
assays were performed in triplicate, n=3 separate experiments.
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Xenograft Studies
MCF-7 vector control and MKP3-transfected cells were established as xenografts in 
ovariectomized 5- to 6-week-old BALB/c athymic nude mice (Harlan Sprague Dawley, 
Madison, WI) supplemented with 0.25-mg 21 day release E2 pellets (Innovative Research, 
Sarasota, FL) by inoculating the mice subcutaneously with 5 × 106 cells, as described 
previously {Osborne, 1995 #2257}. Two vector control animals and 1 MKP3 injected 
animal failed to develop measurable tumors. These were eliminated from the analysis. When 
tumors reached ~250 mm3 (i.e., in 21 days) animals were randomly allocated to continue E2 
(n=6 per group), or to estrogen withdrawal plus Tam (n=4-5 per group; 500 μg/animal given 
subcutaneously in peanut oil, 5 days/week) for another 30 days. Tumor growth was assessed 
and tumor volumes were measured as described previously (12). Tumor growth curves were 
fitted to an exponential growth model and tested for whether the growth rates were different 
for the cell line groups. This was implemented by log-transforming the tumor sizes and 
using a mixed linear model with fixed main effects for cell line and time, a random subject 
effect, and an autoregressive convariance structure within subject. Analyses were carried out 
using SAS (V9.1, Cary, NC).
Anchorage-Independent Growth Assays
Cells were starved for 2 days in PRF MEM (InVitrogen) supplemented with 5% fetal bovine 
serum (FBS, Summit Biotechnology, Fort Collins, CO), 6 ng/ml insulin, 200 units/ml 
penicillin, and 200 μg/ml streptomycin. Soft agar assays were performed in six-well plates. 
After 14 days, the colonies were fixed, and the colony number of colonies >50 cells from 
quadruplicate assays were then counted. The data shown is the mean colony number of four 
plates, and is representative of two independent experiments analyzed for statistical 
significance (p>0.05) using a two-tailed Student’s t-test,or one-way Anova test.
Results
MKP3 Overexpression and TR
To identify genes whose expression was associated with the development of TR, we 
compared primary tumors from patients that did not relapse after Tam treatment despite 7 to 
10 years of follow-up with metastatic tumors from patients that progressed during adjuvant 
Tam treatment using expression microarray analysis. Our rationale was that we might be 
more likely to identify genes whose differential expression was involved in the initiation of 
TR, and whose expression might itself be affected by Tam treatment with our selection 
criteria. Gene expression analysis of our cohort identified MKP3 as being more highly 
expressed in the Tam-resistant (Tam Res) tumor group as compared to the Tam-sensitive 
(Tam Sen) tumor group (Fig. 1, p=0.006). The median level of MKP3 RNA was 2.5 fold 
higher in the Tam Res group. Quantitative RT-PCR assay was also used to confirm 
differential MKP3 RNA expression levels in these tumors; the correlations between 
Affymetrix MKP3 RNA expression and qRT-PCR levels were very high (data not shown; 
Rsp=0.83. p=0.0053).
We next measured the endogenous levels of MKP3 RNA in two in vitro-derived models of 
TR using qRT-PCR; both of these models were derived by long-term culture in Tam-
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containing medium (13). The levels of MKP3 RNA were 19 and 8-fold higher in MCF-7/TR 
and T47D/TR cells, respectively, compared to the parental WT control cell lines (Fig. 1B). 
In addition, we measured MKP3 RNA levels in the Ishikawa endometrial cancer cell line 
where Tam is known to act as an agonist (9). We found very high levels of MKP3 RNA in 
the Ishikawa line, compared to all of the breast cancer cell lines. Finally, we investigated 
whether estrogen or Tam treatment of MCF-7 cells modulated MKP3 RNA levels (Fig. 1C), 
however neither treatment altered MKP3 expression. These data collectively suggest that 
MKP3 levels may be correlated with the TR phenotype in patients and cell lines.
We next generated several models of TR, first stably transfecting ERα-positive MCF-7 cells 
with either empty vector plasmid as a control, or a plasmid encoding MKP3. Cells were drug 
selected for plasmid expression, cloned by limiting dilution, and several resulting clones 
were screened for expression of MKP3 using an anti-V5 antibody to the V5 tag introduced 
at the carboy-terminus of MKP3 (11). An immunoblot analysis of two MCF-7-control 
clones (Fig. 2A, Con 1 and 2) and two MCF-7-MKP3-overexpressing clones (Fig. 2A, 
MKP3-1 and 2) demonstrated similar ectopic expression of MKP3 in the stable 
transfectants. The relative MKP3 RNA levels in clone MKP3.1 were approximately 15-fold 
higher than RNA levels in the vector-alone transfected Con 1 cells (Fig. 2B), a difference 
which was similar to that found in the MCF-7/TR cells (Fig. 1B).
The growth characteristics of the MCF-7 stable MKP3 transfectants under different 
hormonal conditions were investigated using anchorage-independent soft agar assays (Fig. 
2C). As expected, MCF-7 vector control cells exhibited low colony formation in the absence 
of E2 (C1 and C2, C treatment); treatment with E2 increased the number of colonies, and 
Tam treatment reduced the number of colonies of control cells. Ectopic expression of MKP3 
reduced the number of colonies formed in soft agar under estrogen-deprived conditions 
(MKP3-1 and MKP3-2, C) compared to the control transfectants (p=0.0037), however 
estrogen-induced colony formation of the MCF-7-MKP3 clones was equivalent to those 
obtained with vector control cells. In contrast, the number of soft agar colonies formed in the 
presence of Tam was increased ~10-fold in the two MKP3-overexpressing transfectants 
compared to vector control cells (p=0.001). Both the steroidal ERα antagonist ICI182,780, 
and the MEK1,2 inhibitor PD98059 completely blocked Tam-induced colony formation in 
vector control and MKP3-transfected cells. These results suggest that whereas the basal 
growth of MCF-7-MKP3 cells may be negatively affected concomitant with MKP3 
overexpression, Tam treatment either relieves this growth suppression or acts as an agonist 
to increase the colony forming efficiency of MKP3-overexpressing breast cancer cells.
We also engineered TR Ishikawa cells to stably overexpress V5-MKP3 or used a siRNA to 
knockdown MKP3 in this cell line (Fig. 2D and E, respectively). In Ishikawa cells, increased 
levels of MKP3 did not affect control colony growth, but significantly enhanced growth was 
seen in the estrogen and Tam-treated MKP3 transfectants (Fig 2D, lower panel, p= 0.03 and 
p=0.001, respectively). Conversely, when relative MKP3 RNA levels were decreased by 
approximately 45% using siRNA (Fig. 2E, upper panel, p<0.05), there was a decrease in 
Tam colony growth in the Tam treated group (Fig. 2E, lower panel, p=0.02). MKP3 siRNA 
did not affect estrogen-stimulated growth however in Ishikawa cells.
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To analyze the endocrine sensitivity of MKP3-overexpressing cells, we next examined their 
ability to form tumors in athymic nude mice. We established xenografts in ovariectomized 
mice supplemented with estrogen for 21 days. Mice were then randomized to continue 
estrogen treatment or subjected to estrogen withdrawal plus Tam (Fig. 2F and G), and tumor 
growth was monitored over time. The main questions we addressed were whether MKP3-
expressing tumors grew differently in the presence of estrogen, and whether they responded 
similarly to Tam treatment. This was examined by fitting the data in an exponential growth 
model, and testing whether growth rates were different between the groups; the analyses 
were done separately for estrogen-treated (Fig. 2F) and Tam-treated animals (Fig. 2G). We 
found that although MKP3-expressing tumors were slightly larger in size at 21 days 
compared to control tumors, there was no difference in the estrogen-stimulated exponential 
growth rate of the MCF-7 vector control transfected and MKP3-overexpressing cells 
(P=0.52). In contrast, the growth rate of MKP3-expressing cells was significantly increased 
in Tam-treated tumors (P=0.047). These in vivo data thus recapitulate what we observed in 
the soft agar assay in MCF-7 and Ishikawa cells, and with our discovery of higher levels of 
MKP3 RNA in Tam-resistant breast tumors.
Cross-Talk between MKP3, ERK1,2 MAPKs, and the ERα Signaling Pathways
Since there are conflicting reports concerning whether estrogen stimulation activates MAPK 
in MCF-7 breast cancer cells (14, 15), we next assessed the effects of estrogen and Tam on 
the activation of MAPK in MCF-7 vector controls and MKP3 transfectants (Fig. 3A, Con 1 
and 2, and MKP3-1 and 2). Cells were maintained under estrogen-depleted conditions for 2 
days, treated for 2 hours with either estrogen or Tam, and cellular extracts prepared. 
Immunoblot analysis with anti-V5 was used to detect ectopic MKP3 expression in the two 
MKP3 transfectants (Fig. 3A, top panel); immunoblotting with an antibody to Rho GDI was 
used as a loading control in these experiments. In vector-alone transfectants, pMAPK was 
not induced with either short-term (2-30 minutes, data not shown), or two hours of hormonal 
treatment (Fig. 3). In contrast, higher levels of pMAPK were seen in the control and Tam-
treated MKP3-overexpressing cells compared to that seen in the estrogen-treated cells (Fig. 
3A and B). These results were rather paradoxical, in that we predicted to find lower levels of 
pMAPK in cells concomitant with MKP3 overexpression, but instead observed hormonal 
influences on the ability of overexpressed MKP3 to modulate pMAPK. Levels of total 
MAPK did not appear to be affected by MKP3 overexpression. The highest activation of 
MAPK was observed in the Tam-treated MKP3-overexpresing cells (graphically represented 
in Fig. 3B).
ERα is a downstream target of pMAPK in breast cancer cells (3). We observed that levels of 
phosphorylation at ERα serine 118 (pS118 ERα) were highly induced with Tam treatment in 
the MKP3 transfectants (Fig. 3A and C). The question is whether this dramatic induction 
with Tam was coupled with changes in the levels of total ERα? It has been demonstrated 
that ERα undergoes estrogen-dependent down regulation via the proteasomal degradation 
pathway (16). Down regulation of ERα protein was observed in both control transfected and 
the MKP3 overexpressing cells in the presence of estrogen. Similarly, it has been reported 
that Tam stabilizes the receptor (17), and this stabilization was observed in both groups of 
transfectants. Thus, although ERα hormonal regulation appeared to proceed normally, 
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higher levels of pERα were induced by Tam in the MKP3 overexpressing cells, which was 
not associated with higher levels of total ERα as compared to control treated cells.
We next tested the effect of the MEK1,2 inhibitor PD98059 on the ability of Tam to induce 
phosphorylation of MAPK and ERα in MKP3 overexpressing cells (Fig. 3D). We found that 
PK98065 effectively inhibited the increase in pMAPK and pS118 ERα in control and Tam-
treated MKP3.2 cells. The MEK inhibitor also blocked activation of MAPK in vector 
control cells under all the treatment conditions. This result suggests that Tam’s effects in 
MKP3 overexpressing cells involve the MEK-ERK MAPK signaling pathway.
As a control we examined the levels of MKP1, which is also a major negative regulator of 
ERK1/2, but is more specific for JNK and p38, but did not see changes in the levels of 
MKP1 concomitant with MKP3 overexpression (Fig.3E). We observed an increase in pJNK 
in MKP3 transfectants under all hormonal conditions. When vector control cells were 
treated with the MEK1,2 inhibitor, pJNK was elevated, and similarly we found higher levels 
of JNK activation in MKP3 transfectants in the presence of the inhibitor. These results were 
not expected, and suggest that the MEK inhibitor might affect the decreased levels or 
activity of another MKP which could up-regulate pJNK. This possibility is currently under 
study, but suggests that treatment of breast cancer cells with MEK inhibitors might 
concomitantly increase JNK signaling in cells, a consequence which might have therapeutic 
relevance in resistant disease necessitating combination therapy with signal transduction 
inhibitors.
We next questioned whether either changes in MKP3 phosphatase activity or changes in 
binding between MKP3 and ERK2 might underlie the changes in pMAPK. Using the 
artificial substrate pNPP to measure endogenous phosphatase activity in MKP3 and vector 
control cells, we found an inverse relationship between measured MKP3 phosphatase 
activity and pMAPK levels in the MKP3 transfectants compared to the vector control. As 
shown in Fig. 3F, levels of MKP3 phosphatase activity were highest in the estrogen-treated, 
lowest in Tam, and intermediate in the control-treated cells. These findings in activity were 
inversely related to the levels of pMAPK in MKP3 overexpressing cells (Fig. 3A). These 
results suggest that Tam might influence the ability of MKP3 to negatively regulate MAPK. 
We did not however observe changes in the ability of MKP3 to bind to MAPK as measured 
by co-immunoprecipitation and immunoblot analysis (Fig. 3G). When the levels of MKP3-
bound ERK2 were compared between the different hormonal treatments, no differences 
were detected (C, E, T, IP:V5 lanes). Control levels of MKP3 and ERK2 were also 
examined in the pre-IP and post-IP extracts to ensure that adequate pulldown of IP proteins 
were obtained; no differences were detected. Thus, hormonal modulation of MKP3 
phosphatase activity, but not changes in the ability of MKP3 to interact with MAPK may be 
a determinant of MAPK activation in breast cancer cells.
ER Regulated Gene Transcription
CCND1 is an estrogen-induced protein, and is also a downstream marker of activated 
MAPK signaling in breast cancer cells (18). High levels of CCND1 were found in Tam-
treated MKP3 overexpressing cells using immunoblot analysis (Fig. 4A, top panel); 
densitometric scanning of the CCND1 immunoblot is shown in Fig. 4B. Thus, the Tam-
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stimulated soft agar growth and xenograft growth we observed concomitant with MKP3 
overexpression was coupled with the induction of the MAPK downstream marker of 
proliferation, CCND1. These results suggest that the Tam-resistant phenotype of the MKP3 
overexpressing cells is associated with a biomarker of clinical resistance, elevated CCND1, 
downstream of MAPK activation. We also evaluated the RNA levels of CCND1 and c-fos, 
that is a known downstream marker of MAPK activation, in our TR patient samples, and 
found significant correlations between CCND1 (Rsp=0.83, p=0.0053), c-fos (Rsp=0.74, 
p=0.01) and MKP3 (data not shown).
We have previously shown that prolonged treatment of MCF-7 cells grown as xenografted 
tumors in athymic nude mice results in oxidative stress (19), and it is well known that Tam 
can induce oxidative stress and increase reactive oxygen species (ROS) (20). Furthermore, 
during oxidative stress MKP3 phosphatase is inactivated in cortical neurons (21). To explore 
mechanisms associated with MKP3 TR, we therefore measured ROS using a flurogenic 
probe in MKP3 overexpressing MCF-7 cells after hormonal treatments (Fig. 5A). Levels of 
ROS were significantly higher in both the control (serum deprived) and Tam-treated, but 
lowest in the estrogen-treated cells (one-way Anova p=0.0029). Furthermore, treatment with 
the antioxidant glutathione (GSH) increased MKP3 phosphatase activity in control 
(p=0.026) and Tam-treated MKP3 overexpressing cells (p=0.0012) (Fig. 5B), but did not 
affect total levels of exogenous MKP3 (Fig. 5C). Treatment with GSH also effectively 
inhibited TR growth in soft agar, but did not affect either control or estrogen-induced growth 
(Fig. 5D). In agreement with the reversal of resistance after treatment with the antioxidant 
GSH, we observed inhibition of activated MAPK, and reduction in pS118 ERα levels with 
combined GSH and Tam treatment of MKP3.2 transfectants (Fig. 3E). These combined 
results suggest that increases in ROS which can be reversed with an antioxidant may 
underlie the resistant phenotype in our model, and furthermore that MKP3 activity and 
downstream signaling in TR cells are sensitive to changes in intracellular redox status in 
breast cancer cells.
MKP3 is a member of a large family of MAPK phosphatases with different specificities, so 
we next explored whether this identified TR mechanism extended to the prototypical dual 
specificity phosphatase MKP1. This is of interest because MKP1 activity can be modulated 
by mitogens and oxidative stress (4). Using two siRNAs to MKP1 we were able to 
effectively knockdown MKP1 levels in Ishikawa cells (Fig. 6A). Reduction of MKP1 levels 
in the two MKP1 siRNA clones si615 and 1126 resulted in increased TR growth of Ishikawa 
cells in soft agar compared to a control siRNA clone (Fig. 6B, p=0.0031). Levels of 
pMAPK were elevated after both estrogen and Tam treatment in MKP1 siRNA Ishikawa 
clones (Fig. 6C). Thus, enhanced Tam activation of MAPK was associated with decreased 
MKP1 levels, but since MKP1 is at least as effective in phosphorylating JNK and p38 as 
MAPK, the precise role of MKP1 in TR remains to be elucidated. We conclude that 
activation of MAPK in the presence of Tam is important for the resistant phenotype 
associated with MKPs.
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Discussion
Tam has been the most frequently prescribed antiestrogen for the treatment of women with 
early-stage and metastatic ERα-positive breast cancer. Although many patients will initially 
benefit from Tam treatment, the emergence of resistance is a major clinical problem. It has 
been hypothesized that growth factor receptor pathways might impact on ERα activity, and 
hence Tam effectiveness. Increased dependence on MAPK signaling has been previously 
demonstrated to be important for both TR and adaptive resistance to estrogen deprivation in 
MCF-7 cells (22, 23). We identified MKP3, a negative regulator of MAPK, as being 
expressed at higher levels in Tam-resistant metastatic lesions, and demonstrated in 
preclinical studies that its overexpression can confer Tam-resistant growth of cells in vitro or 
as xenografts in athymic nude mice.
We employed microarray expression profiling to identify genes associated with Tam 
resistance in breast cancer patients as a means of exploring new regulatory mechanisms 
operative during the selective pressure of Tam treatment. Recently a two-gene expression 
Tam prediction model was developed using microarray analysis comparing primary breast 
tumors from patients treated with adjuvant Tam who remained disease-free, to those patients 
who developed distant recurrence (24). Although these results have been recently challenged 
(25), microarray technologies have shown great promise in identifying molecular features of 
hormone responsiveness (26). Our study differed in both experimental design and goal 
compared to the microarray study of Ma et al. (24). Although we used a similarly-defined 
Tam sensitive group of primary tumors, we chose to compare these to metastatic lesions 
from patients who recurred while on Tam, with the goal to identify gene candidates that we 
could then examine further for a mechanistic role in resistance. Neither Ma et al. (24), or a 
similarly designed microarray study reported by Jansen et al. (26) found MKP3 RNA levels 
to be differentially associated with the outcome of Tam-treated primary tumors. We attribute 
this difference to be due to either experimental design, or in the diverse array platforms 
utilized between the studies. Interestingly, we found that the levels of pMAPK protein were 
highest in Tam-treated and lowest in the presence of estradiol when MCF-7 cells were 
engineered to overexpress MKP3. We found that MEK inhibition reversed Tam-induced soft 
agar growth of MKP3 overexpressing MCF-7 cells, further implicating MAPK signaling in 
resistance in our model. These results suggest that activated MAPK remains a common 
component of Tam-resistant growth in preclinical models.
We demonstrated that MKP3 enzymatic activity was particularly sensitive to regulation by 
hormones, and we propose that its hormonal modulation may be an alternative and novel 
mechanism by which ERK1,2 can be activated and regulated in breast cancer cells. 
Mechanistically our data demonstrate that this hormonal regulation is associated with 
alterations in the redox state of the cell, with high ROS coincident TR growth and low 
MKP3 activity. The use of an antioxidant to reverse resistance confirms the role of oxidative 
stress in the process. Several of the MKPs are known to be induced following exposure to 
stress and/or growth factor stimulation (4), however MKP3 has not been previously 
demonstrated to be regulated by these stimuli. Recently, it has been shown that the activity 
of MKP3, rather than its expression, was downregulated by oxidative signals (21), possibly 
through oxidizing critical cysteine residues.
Cui et al. Page 10
Cancer Res. Author manuscript; available in PMC 2015 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
There is also evidence for multiple, temporally discrete pathways which differentially 
regulate MAPK depending on the external stimulus. For instance, fibroblast growth factor 
(FGF) 1 and heregulin β1-induced TR in MCF-7 cells is also associated with prolonged 
MAPK activation that is incompletely susceptible to MEK inhibitors (27). Our results 
suggest that Tam increases ERK1,2 activity via the loss of MKP3 phosphatase activity, an 
alternative “off-off” mechanism of resistance which remains sensitive to MEK inhibition. 
Therefore, patients with Tam-resistant disease and elevated MKP3 may be markedly 
sensitive to MEK inhibitors or antioxidants.
ERα expression is lost in a minority of recurrent metastatic lesions after Tam treatment (28). 
Thus, our model is different from hyperactivation of the Raf1/MEK1 signaling pathway 
which leads to a down-regulation of ERα, and potentially reflects the more common 
resistance mechanisms associated with continued ERα expression in patients. We have 
shown that PKA signaling induces ERα S305 phosphorylation, which is coupled to 
acetylation at K303 within the hinge domain and estrogen sensitivity (29). This site has been 
demonstrated to be important for Tam resistance (30) and expression of CCND1 (31). The 
ERα S118 site is phosphorylated in response to epidermal growth factor signaling, possibly 
via pMAPK (32), and by activated ERK1,2 in breast cancer cells (3). ERα S118 was 
phosphorylated in response to Tam in MKP3 overexpressing cells, which was associated 
with higher pMAPK levels. However, high levels ERα pS118 have been shown to be 
associated with a better disease outcome in breast cancer patients treated with Tam in one 
clinical study (33). Therefore the usefulness of pS118 as a clinical marker of resistance 
requires further study.
We hypothesize that MKP3 may be a novel target of Tam action. It is possible that breast 
tumors may compensate for chronic activation of MAPK by up-regulation of phosphatases, 
such as MKP3, that control these pathways. The emergence of Tam resistance may therefore 
involve the disruption of this regulatory compensatory loop by inactivation of MKP3 
phosphatase activity explaining the seemingly paradoxical up-regulation of MKP3 levels, 
but down-regulation of its activity in Tam-treated MKP3 overexpressing cells.
We also detected activation of JNK with MEK1 inhibitor treatment of MCF-7 cells, with 
further enhanced JNK phosphorylation noted in our MKP3 overexpressing cells. Whether 
down-regulation of other MKPs may be associated with this effect, and whether combined 
MAPK inhibitors with Tam treatment are efficacious in our model is currently under study 
in our laboratory. It is tempting to speculate that MKP3 expressing tumors might be 
sensitive to estrogen deprivation (aromatase inhibitor treatment), given our finding that there 
was limited growth of MKP3 overexpressing breast cancer cells in the absence of estrogen. 
In summary, this study suggests that MKP3 may be an attractive new diagnostic and 
potentially therapeutic target in breast cancer.
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Fig. 1. 
A. Scatter plot of MKP3 RNA expression in 9 tumors; 4 tumors were Tam sensitive and 5 
were Tam-resistant. Circles show the individual RNA values in arbritary units. Parametric p-
value = 0.006; permutation p-value adjusted for multiple comparisons = 0.09. B. Relative 
MKP3 mRNA levels were determined using qRT-PCR in various cell lines. Relative levels 
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were normalized to the levels of 18S ribosomal RNA in each RNA sample. C. Relative 
MKP3 mRNA levels of MCF-7 cells treated with estrogen (E2, 10 nM) or Tam (Tam, 100 
nM) for 24 hours. Relative MKP3 RNA levels were normalized to the levels of 18S 
ribosomal RNA in each RNA sample.
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Fig. 2. 
A. Immunoblot (IB) analysis of two vector-alone, control transfected MCF-7 clones (Con 1 
and 2), and two MKP-3 transfected clones (MKP3-1 and 2). A V5 epitope tag was included 
in the expression vector and was used for visualization of MKP3 levels. B. Relative MKP3 
levels in Con1 and MKP3.1 transfectants were determined using qRT-PCR. Levels were 
normalized to 18S ribosomal RNA in each sample. C. Anchorage-independent colony 
formation assay with the above transfectants in the presence of 1.0 nM estrogen (E2), 100 
nM tamoxifen (Tam), 100 nM Tam + 10 nM ICI 182,780, or 100 nM Tam + 20 nM 
PD98059. The mean colony number was assayed after growth under the respective treatment 
conditions for 14 days and statistical significance was assessed using a two-tailed Student’s 
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t-test; **significance level at p<0.05. D. Immunoblot analysis of vector-alone, control 
transfected Ishikawa cells (Con), and a MKP-3 transfected Ishikawa cell (MKP3) (upper 
panel). A V5 epitope tag was included in the expression vector and was used for 
visualization of MKP3 levels. Anchorage-independent colony formation assay with the 
Ishikawa transfectants in the presence of ethanol (C), estrogen (E2) or Tam. The mean 
colony number was assayed after growth under the respective treatment conditions for 14 
days and statistical significance was assessed using a two-tailed Student’s t-test; 
**significance level at p<0.05. E. Knockdown of MKP3 in Ishikawa cells was performed 
using a siRNA to MKP3. Relative MKP3 levels in control siRNA transfected (Ctrl Si) and 
MKP3 siRNA transfectants were determined using qRT-PCR (upper panel). Colony 
formation assays were performed in the presence of ethanol vehicle (C), 1.0 nM E2 and 100 
nM Tam (lower panel). ** significance level at p<0.05 using a two-taileld Student’s t-test. F. 
and G. MCF-7-vector control 1 and MCF-7-MKP3-2 cells were injected into athymic nude 
mice supplemented with E2 for 21 days, and then randomly assigned to either continue E2 
treatment (F.), or to have their E2 pellets removed and were treated with Tam (G.). There 
were n=6 animals each for the E2-treated vector control, and MKP3-overexpressing cells; 
there were n=4 for Tam-treated vector control, and n=5 animals for the Tam-treated MKP3-
overexpressing cells.
Cui et al. Page 19
Cancer Res. Author manuscript; available in PMC 2015 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Cui et al. Page 20
Cancer Res. Author manuscript; available in PMC 2015 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 3. 
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A. Immunoblot analysis of two vector control (Con 1 and 2), and two MKP3-overexpressing 
transfectants (MKP3-1 and 2) treated for 2 hours with ethanol vehicle (C), 100 nM E2 (E), 
or 100 nM Tam (T). Immunoblots were stained with antibodies to V5 to demonstrate MKP3 
levels, or to pMAPK, total MAPK, ERα S118, total ERα antibodies, and anti-Rho GDI as a 
loading control. B. Densitometric scan of the immunoblot in panel A showing levels of 
pMAPK normalized to Rho GDI levels. C. Densitometric scan of the immunoblot in panel A 
showing levels of pS118 normalized to Rho GDI levels. D. An immunoblot analysis of 
MKP3 Con 1 and MKP3-2 transfectants treated with vehicle, E2, or Tam for 2 hours in the 
absence(-) or presence of 20 nM PD98059. Immunoblots were stained with antibodies to 
V5, phospho-pMAPK and S118 ERα, or total MAPK and ERα. E. An immunoblot analysis 
of MKP3 Con 1 and MKP3-2 transfectants treated with vehicle, E2, or Tam for 2 hours in 
the absence(-) or presence of PD98059. Immunoblots were stained with antibodies to 
MKP1, phosphoJNK, and total JNK. F. Phosphatase assay using pNPP as a substrate using 
extracts prepared from MKP3 vector 1 and MKP3-2 cells treated for 2 hours with vehicle, 
E2, or Tam. The nonenzymatic hydrolysis of the substrate was corrected (absorbance at 405 
nm) by subtracting the control vector transfected immunoprecipitates, from MKP3 levels 
and expressed as MKP3-Vector 405 nM. Phosphatase assays were performed in triplicate, 
n=3 separate experiments shown. G. MKP3/MAPK binding assay was performed with 
MKP3 Con 1 and MKP3-2 transfectants treated for 2 hours with ethanol vehicle (C), E2 (E), 
or Tam (T). Pre- and Post-V5 immunoprecipitated extracts (Pre-IP and Post-IP) were 
immunoblotted with antibodies to ERK2 and V5 to demonstrate levels of MAPK and 
MKP3, arrows respectively. Immunoglobulin heavy chain (HC) and light chain (LC) are 
shown. The specificity of the V5 and ERK2 antibodies are shown in the previous figures.
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Fig. 4. 
A. Immunoblot analysis of two vector control (Con 1 and 2), and two MKP3-overexpressing 
transfectants (MKP3-1 and 2) treated for 2 hours with ethanol vehicle (C), 100 nM E2 (E), 
or 100 nM Tam (T). Immunoblots were stained with antibodies to CCND1, and anti-Rho 
GDI as a loading control. B. Densitometric scan of the immunoblot in panel A showing 
levels of CCND1 normalized to Rho GDI levels.
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Fig. 5. 
A. ROS levels in MKP3.2 MCF-7 cells treated for 2 hours with ethanol vehicle (C), 100 nM 
E2, or 100 nM Tam. were measured using the fluorogenic DCF. B. MKP3 phosphatase 
activity was examined in MKP3.2 and vector Con 1 control cells in the presence of 
hormonal treatments and GSH. C. Immunoblot of exogenous MKP3 levels in cells from 
panel B using an antibody to the V5 tag. D. Anchorage-independent colony formation assay 
with the above transfectants in the presence of vechicle, 1.0 nM E2, 100 nM Tam +/− 100 
μM GSH. The mean colony number was assayed after growth under the respective treatment 
conditions for 14 days. E. An immunoblot analysis of MKP3 Con 1 and MKP3.2 
transfectants treated with vehicle, E2, or Tam for 2 hours in the absence(-) or presence of 
GSH Immunoblots were stained with antibodies to pMAPK, pS118 ERα, total Erk1/2, total 
ERα, and V5 to detect exogenous MKP3.
Cui et al. Page 25
Cancer Res. Author manuscript; available in PMC 2015 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 6. 
A. Immunoblot analysis of vector-alone, control siRNA transfected Ishikawa cells (Ctrl Si ), 
and two MKP1 siRNA transfected Ishikawa cell polls (Si615 and 1126). MKP1 and total 
Erk1/2 levels were measured. B. Anchorage-independent colony formation assay with the 
above Ishikawa transfectants in the presence of ethanol (C), 1.0 nM E2 or 100 nM Tam. The 
mean colony number was assayed after growth under the respective treatment conditions for 
14 days and statistical significance was assessed using a two-tailed Student’s t-test; 
**significance level at p<0.05. C. Immunoblot analysis of Ctrl SiRNA and two MKP1 
siRNAs after treatment with ethanol (C), 100 nM E2, or 100 nM Tam using antibodies to 
pMAPK and total Erk2.
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